POSTAFEN

Main information

  • Trade name:
  • POSTAFEN 25 mg tablet
  • Dosage:
  • 25 mg
  • Pharmaceutical form:
  • tablet
  • Prescription type:
  • Prescription partly
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • POSTAFEN 25 mg tablet
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Meclozine
  • Product summary:
  • Suitability for use in older adult patients Meclozini dihydrochloridum Avoid use in older persons. Anticholinergic. Sedative. Significant adverse effects include xerostomia, constipation, dizziness, tachycardia, urinary difficulties, confusion, cognitive disorder, tiredness, orthostatic hypotension and risk for falls. Weakens the efficacy of anti-Alzheimer´s drugs.

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 3393
  • Authorization date:
  • 15-05-2008
  • Last update:
  • 21-02-2018